Continuing where they left off at the end of the second quarter, global biotechs recorded yet another positive quarter. However, the fundraising pace did slow down reflecting what proved to be a comparatively quiet summer period. Nevertheless, more than $4 billion was banked by public and private companies in the third quarter of 2013, a 29 percent drop from the almost $6 billion that was raised in the second quarter and 17 percent shy of the total generated in Q1 2013.